Novo Nordisk faces slowing growth, competition, regulatory risks, and Wegovy pricing pressure, with DCF showing fair valuation. See why NVO stock is a hold.

GLP-1 drugs mimic the GLP-1 hormone in the body, which helps to treat type 2 diabetes and obesity. In India, GLP-1 RAs are ...

Investing.com -- The Medicines and Healthcare products Regulatory Agency approved a maximum dose of up to 7.2 milligrams per week of Novo Nordisk’s (CSE:NOVOb) weight-loss drug Wegovy for patients ...

Danish national registry data suggest adults with type 2 diabetes taking SGLT2 inhibitors have a slightly lower risk of developing diabetic foot problems than those taking GLP-1 receptor agonists.

The U.K. medicines regulator stated that the maximum dose of 7.2 mg of Wegovy only applies to adult patients with a Body Mass ...

The once-a-day semaglutide pill is approved for reducing the risk of heart disease and Type 2 diabetes, the company said in a statement Monday.

People with type 2 diabetes face a higher risk of heart attacks, strokes and other cardiovascular problems, according to the National Institutes of Health. These risks also differ between women and ...

The iShares MSCI Denmark ETF is rated a buy, supported by Denmark’s strong fundamentals and macroeconomic tailwinds. Learn ...

People with type 2 diabetes face a higher risk of heart attacks, strokes and other cardiovascular problems, according to the ...

Federal health regulators say popular weight loss drugs like Wegovy and Zepbound do not increase the risk of suicidal ...

As 25 pounds slid away, she felt less tired and found herself walking and biking more. Then her Medicare plan notified her it ...

Meanwhile, the FDA has asked manufacturers of flu vaccines to update their labels to include warnings about the risk of ...